Why Viking Therapeutics Stock Was Victorious This Week

Core Insights - Viking Therapeutics has seen a significant stock price increase of nearly 18% over the past week, driven by the potential support from the World Health Organization (WHO) for obesity medications [1][2] - The WHO is preparing to officially endorse the use of obesity drugs for adults, aiming to enhance access for lower- and middle-income patients [2] - The U.S. market for weight-loss drugs is currently dominated by Novo Nordisk's Wegovy and Eli Lilly's Zepbound, which have gained popularity due to their effectiveness compared to traditional weight loss methods [4] - Viking's VK2735 has shown promising results in phase 2 clinical trials, positioning the company as a strong competitor in the weight-loss drug market [5] - The global obesity issue presents a vast market opportunity for Viking and its competitors, especially with the WHO's backing [6]